乳腺癌多藥耐藥性研究進展_《中國普外基礎與臨床雜志》

作者：

趙菲 , 姜軍

第三軍醫大學西南醫院乳腺中心（重慶400038）;

關鍵詞：

乳腺腫瘤化學治療藥物耐受性

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的綜述乳腺癌多藥耐藥性研究的最新進展。
方法采用文獻回顧的方法，對目前國內、外有關乳腺癌多藥耐藥性的研究狀況加以分析與綜述。
結果乳腺癌多藥耐藥是多基因、多階段、多步驟、多因素共同作用的結果。如何早期明確化療藥物的敏感性并選擇適宜的個體化治療方案，是避免化療失敗，提高患者生存率和生活質量的一個重要環節。
結論深入研究乳腺癌多藥耐藥的發生、發展機理，有助于臨床預測化療療效，分析患者預后，并為最終解決多藥耐藥這一難題提供有益的幫助。

引用本文： 趙菲,姜軍. 乳腺癌多藥耐藥性研究進展. 中國普外基礎與臨床雜志, 2004, 11(1): 36-39. doi: 復制

1.	Arnal M, Franco N, Fargeot P, et al. Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancer [J].Breast Cancer Res Treat, 2000; 61(1)∶13.
2.	Schneider J, GonzalezRoces S, Pollan M, et al. Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue m astectomy after induction chemotherapy [J]. Breast Cancer Res, 2001; 3(3)∶183.
3.	Ratnasinghe D, Daschner PJ, Anver MR, et al. Cyclooxygenase2, Pglycoprotein170 and drug resistance; is chemoprevention against multidrug resistance possible?[J]. Anticancer Res, 2001; 21(3C)∶2141.
4.	Beck J, Bohnet B, Brugger D, et al. Multiple gene expression analysis reveals distinct differences between G2 and G3 stage breast cancers, and correlations of PKC eta with MDR1, MRP and LRP gene expression [J].Br J Cancer, 1998; 77(1)∶87.
5.	Lucci A, Cho WI, Han TY, et al. Glucosylceramide: a marker for multipledrug resistant cancers [J]. Anticancer Res, 1998; 18(1B)∶475.
6.	Liu YY, Han TY, Giuliano AE, et al. Ceramide glycosylation potentiates cellular multidrug resistance [J]. FASEB J, 2001; 15(3)∶719.
7.	Chandrasekharan NV, Dai H, Roos KL, et al. COX3, a cyclooxygenase1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression [J]. Proc Natl Acad Sci USA, 2002; 99(21)∶13926.
8.	Janz M, Harbeck N, Dettmar P, et al. Ybox factor YB1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI1 [J]. Int J Cancer, 2002; 97(3)∶278.
9.	Jedlitschky G, Burchell B, Keppler D. The multidrug resistance protein 5 functions as an ATPdependent export pump for cyclic nucleotides [J]. J Biol Chem, 2000; 275(39)∶30069.
10.	Kanzaki A, Toi M, Nakayama K, et al. Expression of multidrug resistancerelated transporters in human breast carcinoma [J]. Jpn J Cancer Res, 2001; 92(4)∶452.
11.	Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF7 breast cancer cells [J]. Proc Natl Acad Sci USA, 1998; 95(26)∶15665.
12.	Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues [J]. Cancer Res, 2001; 61(8)∶3458.
13.	Litman T, Brangi M, Hudson E, et al. The multidrugresistant phenotype associated with overexpression of the new ABC halftransporter, MXR (ABCG2) [J]. J Cell Sci, 2000; 113(Pt 11)∶2011.
14.	Faneyte IF, Kristel PM, Maliepaard M, et al. Expression of the breast cancer resistance protein in breast cancer [J]. Clin Cancer Res, 2002; 8(4)∶1068.
15.	Perquin M, Oster T, Maul A, et al. The glutathionerelated detoxification pathway in the human breast: a highly coordinated system disrupted in the tumour tissues [J]. Cancer Lett, 2000; 158(1)∶7.
16.	Jarvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase Ⅱ alpha associate with ErbB2 amplification and affect sensitivity to topoisomerase Ⅱ inhibitor doxorubicin in breast cancer [J]. Am J Pathol, 2000; 156(3)∶839.
17.	Coon JS, Marcus E, GuptaBurt S, et al. Amplification and overexpression of topoisomerase Ⅱ alpha predict response to anthracyclinebased therapy in locally advanced breast cancer [J]. Clin Cancer Res, 2002; 8(4)∶1061.
18.	Fedier A, Schwarz VA, Walt H, et al. Resistance to topoisomerase poisons due to loss of DNA mismatch repair [J]. Int J Cancer, 2001; 93(4)∶571.
19.	Matsumoto Y, Takano H, Kunishio K, et al. Hypophosphorylation of topoisomerase Ⅱ alpha in etoposide (VP16)resistant human carcinoma cell lines associated with carboxyterminal truncation [J]. Jpn J Cancer Res, 2001; 92(7)∶799.

1. Arnal M, Franco N, Fargeot P, et al. Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancer [J].Breast Cancer Res Treat, 2000; 61(1)∶13.
2. Schneider J, GonzalezRoces S, Pollan M, et al. Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue m astectomy after induction chemotherapy [J]. Breast Cancer Res, 2001; 3(3)∶183.
3. Ratnasinghe D, Daschner PJ, Anver MR, et al. Cyclooxygenase2, Pglycoprotein170 and drug resistance; is chemoprevention against multidrug resistance possible?[J]. Anticancer Res, 2001; 21(3C)∶2141.
4. Beck J, Bohnet B, Brugger D, et al. Multiple gene expression analysis reveals distinct differences between G2 and G3 stage breast cancers, and correlations of PKC eta with MDR1, MRP and LRP gene expression [J].Br J Cancer, 1998; 77(1)∶87.
5. Lucci A, Cho WI, Han TY, et al. Glucosylceramide: a marker for multipledrug resistant cancers [J]. Anticancer Res, 1998; 18(1B)∶475.
6. Liu YY, Han TY, Giuliano AE, et al. Ceramide glycosylation potentiates cellular multidrug resistance [J]. FASEB J, 2001; 15(3)∶719.
7. Chandrasekharan NV, Dai H, Roos KL, et al. COX3, a cyclooxygenase1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression [J]. Proc Natl Acad Sci USA, 2002; 99(21)∶13926.
8. Janz M, Harbeck N, Dettmar P, et al. Ybox factor YB1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI1 [J]. Int J Cancer, 2002; 97(3)∶278.
9. Jedlitschky G, Burchell B, Keppler D. The multidrug resistance protein 5 functions as an ATPdependent export pump for cyclic nucleotides [J]. J Biol Chem, 2000; 275(39)∶30069.
10. Kanzaki A, Toi M, Nakayama K, et al. Expression of multidrug resistancerelated transporters in human breast carcinoma [J]. Jpn J Cancer Res, 2001; 92(4)∶452.
11. Doyle LA, Yang W, Abruzzo LV, et al. A multidrug resistance transporter from human MCF7 breast cancer cells [J]. Proc Natl Acad Sci USA, 1998; 95(26)∶15665.
12. Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues [J]. Cancer Res, 2001; 61(8)∶3458.
13. Litman T, Brangi M, Hudson E, et al. The multidrugresistant phenotype associated with overexpression of the new ABC halftransporter, MXR (ABCG2) [J]. J Cell Sci, 2000; 113(Pt 11)∶2011.
14. Faneyte IF, Kristel PM, Maliepaard M, et al. Expression of the breast cancer resistance protein in breast cancer [J]. Clin Cancer Res, 2002; 8(4)∶1068.
15. Perquin M, Oster T, Maul A, et al. The glutathionerelated detoxification pathway in the human breast: a highly coordinated system disrupted in the tumour tissues [J]. Cancer Lett, 2000; 158(1)∶7.
16. Jarvinen TA, Tanner M, Rantanen V, et al. Amplification and deletion of topoisomerase Ⅱ alpha associate with ErbB2 amplification and affect sensitivity to topoisomerase Ⅱ inhibitor doxorubicin in breast cancer [J]. Am J Pathol, 2000; 156(3)∶839.
17. Coon JS, Marcus E, GuptaBurt S, et al. Amplification and overexpression of topoisomerase Ⅱ alpha predict response to anthracyclinebased therapy in locally advanced breast cancer [J]. Clin Cancer Res, 2002; 8(4)∶1061.
18. Fedier A, Schwarz VA, Walt H, et al. Resistance to topoisomerase poisons due to loss of DNA mismatch repair [J]. Int J Cancer, 2001; 93(4)∶571.
19. Matsumoto Y, Takano H, Kunishio K, et al. Hypophosphorylation of topoisomerase Ⅱ alpha in etoposide (VP16)resistant human carcinoma cell lines associated with carboxyterminal truncation [J]. Jpn J Cancer Res, 2001; 92(7)∶799.

《中國普外基礎與臨床雜志》

乳腺癌多藥耐藥性研究進展

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國普外基礎與臨床雜志》

乳腺癌多藥耐藥性研究進展

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料